Singapore biomedical startups expanding into China to accelerate cancer and diabetes treatments

China has reached parity with the United States in the sheer volume of biomedical research output and early-stage drug pipelines, while the U.S. continues to maintain a lead in research influence, high-impact citations, and cutting-edge breakthrough discoveries.
<br>
<br>Research Volume and Early-Stage Pipelines.
<br>• Publication &amp; Output: China has matched or surpassed the U.S. in total scientific publishing and annual biomedical research output, with top institutions in both countries producing roughly 43,500 papers a year, and China accounting for over 32% to 40%+ of global medical research papers.
<br>
<br>• Early-Stage Drug Development: According to data published in JAMA, China&#39;s share of global early-stage drug development programs surged from 8% in 2015 to over 32% by 2024, whereas the U.S. share shifted from 48% down to roughly 37%.
<br>
<br>• Speed &amp; Cost Advantages: Clinical trials and first-in-human studies often move significantly faster and at lower costs in China due to large patient populations and streamlined local processes, prompting a surge in cross-border licensing deals where Western pharma companies license Chinese-developed compounds